Live tape
Top 8, mentions 7d9,317MRNA1,848 mentions▲ +0.09GOOGL1,676 mentions▲ +0.04META1,281 mentions▲ +0.03SNDK1,114 mentions▲ +0.10NVDA1,104 mentions▲ +0.07SPCX868 mentions▲ +0.08NKE737 mentions▲ +0.03MSFT689 mentions▲ +0.05

Equity · Healthcare

AMRN

Amarin Corporation plc · NasdaqCM

$14.07 −2.33% 1D Finazon · prior-day close · Aug 20, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$17 $13 26 May 20 Aug

The line runs $14.35 on 26 May through $14.07 on 20 August, on a scale from $13 to $17. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of AMRN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $14.35 on 26 May 2026 through $14.07 on 20 August 2026.

Market cap $6.0B
52-week range $13.51 – $20.21
Avg volume 8.1K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 20, 2026

AMRN insider trades

SEC Form 4

AMRN has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 August 2025.

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Aug 2025 Fishman Peter L. SVP, CFO Award 312
01 Aug 2025 Fishman Peter L. SVP, CFO Option exercise 312
01 Aug 2025 Fishman Peter L. SVP, CFO Tax withheld 160 $2K

AMRN reported financials

SEC EDGAR XBRL

AMRN reported revenue of $213.6M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$38.8M.

Figure Reported Period
Revenue $213.6M 31 Dec 2025 fiscal year
Net income −$38.8M 31 Dec 2025 fiscal year
Diluted EPS −$0.09 31 Dec 2025 fiscal year
Total assets $624.4M 30 Jun 2026 at period end
Total equity $443.6M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AMRN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.02 —
31 Mar 2026 Q1 2026 $-0.03 —
31 Dec 2025 FY 2025 $-0.09 —
30 Sep 2025 Q3 2025 $-0.02 —
30 Jun 2025 Q2 2025 $-0.03 —
31 Mar 2025 Q1 2025 $-0.04 —
31 Dec 2024 FY 2024 $-0.20 —
30 Sep 2024 Q3 2024 $-0.06 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AMRN institutional holders

SEC Form 13F

4 of the 45 institutional funds we track reported a AMRN position for the quarter ended 30 Jun 2026 — a combined $5.7M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Millennium Management Trimmed −61.5% shares 115,808 $1.8M
Two Sigma Investments Held (±25%) −6.5% shares 100,511 $1.6M
Citadel Advisors Held (±25%) +18.4% shares 95,364 $1.5M
Renaissance Technologies Added +151.2% shares 48,369 $771K
Point72 Asset Management Exited

Source: SEC EDGAR 13F filings

AMRN fails-to-deliver

SEC CNS data

On 27 Jul 2026, 87 shares of AMRN failed to deliver (about $1K).

Settlement date Shares failed Notional % of shares out
27 Jul 2026 87 $1K <0.001%
22 Jul 2026 99 $1K <0.001%

Source: SEC fails-to-deliver (CNS) data